Proactive Investors - Run By Investors For Investors

Imugene to be granted patent for cancer vaccine in Israel

Imugene to be granted patent for cancer vaccine in Israel

Imugene Limited (ASX:IMU) may trade firmer after the Israeli Patent Office issued an Intention to Grant for its proprietary cancer vaccine, HER-Vaxx.

The patent will protect specific cancer vaccine formulations in Israel until 2027.

HER-Vaxx stimulates a polyclonal antibody response to the HER-2/neu receptor, the same biomarker targeted by the $US6.9 billion per annum drug Herceptin®.

HER-2/neu is known to be over-expressed on various tumours including gastric, breast, ovarian and pancreatic cancers.

HERVaxx has completed a Phase 1 study in breast cancer; the next stage of development will be a Phase 2 study in gastric cancer, which is the second most common cause of cancer-related death in the world

Imugene secured full rights to manufacture the cancer immunotherapy as part of its acquisition of BioLife Science in December last year.

The first patent was assigned from Pevion Biotech of Switzerland, protecting Her-Vaxx in several major markets until 2030.

Imugene also holds an exclusive global license covering a patent for the virosome vaccine delivery platform, which is used in the vaccine's manufacture.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.


View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

Cancer cells
February 13 2019
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies
November 19 2018
“It’s a blended model of highly cash generative assets and top line growth”

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use